# US 2003/0211608 A1 · Antisense modulation of glycogen synthase kinase 3 beta expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211608 A1
- Document ID: US20030211608A1
- Status: Published application
- Kind: A1
- Application number: 10/181,543
- Filed: 2002-11-04
- Published: 2003-11-13
- Earliest claimed: 2002-11-04
- Inventors: Madeline M. Butler; Robert McKay; Brett P. Monia; Jacqueline Wyatt
- Web page: https://patentgrep.com/patent/US20030211608A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 207/11026: Tau-protein kinase (2.7.11.26)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.

## Claims

### Claim 1

An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding glycogen synthase kinase 3 beta, wherein said antisense compound specifically hybridizes with and inhibits the expression of glycogen synthase kinase 3 beta.

### Claim 2 (depends on 1)

The antisense compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84 or 85.

### Claim 4 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 5 (depends on 4)

The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 6 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 7 (depends on 6)

The antisense compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

### Claim 8 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 9 (depends on 8)

The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

### Claim 10 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 11 (depends on 1)

A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 11)

The composition of claim 11 further comprising a colloidal dispersion system.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

### Claim 14 (depends on 1)

A method of inhibiting the expression of glycogen synthase kinase 3 beta in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of glycogen synthase kinase 3 beta is inhibited.

### Claim 15 (depends on 1)

A method of treating a human having a disease or condition associated with glycogen synthase kinase 3 beta comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of glycogen synthase kinase 3 beta is inhibited.

### Claim 16 (depends on 15)

The method of claim 15 wherein the disease or condition is an insulin regulation disorder.

### Claim 17 (depends on 16)

The method of claim 16 wherein the insulin regulation disorder is diabetes.

### Claim 18 (depends on 15)

The method of claim 15 wherein the disease or condition is a neurological disorder.

### Claim 19 (depends on 18)

The method of claim 18 wherein the neurological disorder is Alzheimer's disease.

### Claim 20 (depends on 15)

The method of claim 15 wherein the neurological disorder is bipolar illness.
